Combination of urinary fibrinogen β-chain and tyrosine-phosphorylated proteins for the detection of bladder cancer.
bladder cancer
fibrinogen β-chain
tyrosine-phosphorylated proteins
urinary markers
Journal
Future science OA
ISSN: 2056-5623
Titre abrégé: Future Sci OA
Pays: England
ID NLM: 101665030
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
05
05
2021
accepted:
30
08
2021
entrez:
5
11
2021
pubmed:
6
11
2021
medline:
6
11
2021
Statut:
epublish
Résumé
To evaluate the performance of urinary fibrinogen β-chain (FBC) - either alone or associated with urinary tyrosine-phosphorylated proteins (UPY) - as bladder cancer (BCa) diagnostic biomarker. 164 subjects were tested. Significantly different FBC and UPY levels were found between BCa patients and controls, as well as between low-grade and high-grade cancers. The diagnostic accuracy was 0.84 for FBC and 0.87 for UPY. The combination of FBC and UPY improved the accuracy to 0.91. The addition of clinical variables (age, gender, and smoking habit) to FBC and UPY into a model for BCa prediction significantly improved the accuracy to 0.99. The combination of FBC and UPY adjusted for clinical variables associates with the highest sensitivity and good specificity. Urinary FBC and UPY could be used as biomarkers for BCa diagnosis.
Identifiants
pubmed: 34737890
doi: 10.2144/fsoa-2021-0060
pmc: PMC8558871
doi:
Types de publication
Journal Article
Langues
eng
Pagination
FSO758Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
Financial & competing interests disclosure This study was supported by the CRT Foundation Grant (Italy) Progetti Ordinari 2015, Cod. ROL 46644 to G Giribaldi and P Gontero. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.
Références
Eur Urol. 2019 Nov;76(5):639-657
pubmed: 31443960
Proteomics. 2012 Jan;12(1):135-44
pubmed: 22065568
World J Urol. 2020 Jan;38(1):143-150
pubmed: 30993426
BJU Int. 2013 May;111(6):857-64
pubmed: 22757942
World J Urol. 2018 Dec;36(12):1981-1995
pubmed: 29931526
Int J Urol. 2017 Feb;24(2):130-136
pubmed: 28004432
Clin Genitourin Cancer. 2017 Jul 26;:
pubmed: 28822718
J Urol. 1975 Dec;114(6):879-93
pubmed: 1195467
Eur Urol. 1978;4(5):348-50
pubmed: 710466
J Urol. 2017 Jun;197(6):1419-1426
pubmed: 27986532
World J Urol. 2019 Jan;37(1):31-40
pubmed: 30259123
Carcinogenesis. 2018 Oct 8;39(10):1254-1263
pubmed: 30052775
J Urol. 1992 Sep;148(3):788-90
pubmed: 1512826
Ann N Y Acad Sci. 2001;936:406-25
pubmed: 11460495
World J Urol. 2019 Mar;37(3):507-514
pubmed: 29992381
Blood. 2000 Nov 15;96(10):3302-9
pubmed: 11071621
BJU Int. 2013 Aug;112(3):407-15
pubmed: 23470167
Biochim Biophys Acta. 2013 Jun;1830(6):3664-9
pubmed: 23528894
J Thromb Haemost. 2008 Jan;6(1):176-83
pubmed: 17949478
Cancer Res. 1984 Dec;44(12 Pt 1):5886-93
pubmed: 6498846
Urol Oncol. 2010 Jul-Aug;28(4):441-8
pubmed: 20610281
Br J Cancer. 2015 Jul 28;113(3):469-75
pubmed: 26125446
Cochrane Database Syst Rev. 2015 Jan 28;1:CD010007
pubmed: 25626128
Transl Androl Urol. 2021 Feb;10(2):626-635
pubmed: 33718065